SBIR/STTR Research Award
A Safe Analgesic Drug with Addiction Treatment Potential
Award amount
$100,000Program and phase
SBIR · Phase IAward year
2004Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- PHOENIX PHARMALABS, INC.
- Proposal award date
- Not reported
- Contract end date
- Not reported
- UEI
- SK3VX5DEN6E7
- Solicitation number
- PHS2004-2
- Topic code
- Not reported
Research abstract
DESCRIPTION (provided by applicant): This SBIR grant is sought for the purpose of commercializing a promising and needed drug NIH 10497(D-1). It is a novel, orally active opioid with a unique chiral N-substituent that confers an unprecedented activity pr
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
- Identification of Mixed NOP/mu partial agonists as lead compounds for treatment ofmethamphetamine use disorder
- The Kappa Partial Agonist PPL-103 as a Potential Cocaine Abuse Pharmacotherapy
- Unique Opioid Analgesics With No Addiction Liability or Dysphoria
Research funding history
4 SBIR/STTR records share this UEI (2004–2023). Reported award amounts total $806,670. Reported amounts are not federal obligations.
Phases: Phase I
Agencies: Department of Health and Human Services